In the video below, SABCS® Codirector Virginia Kaklamani, MD, and Komal Jhaveri, MD, discuss the recent Phase 3 results from the PIK3CA wild-type disease cohort of the VIKTORIA-1 trial, in which gedatolisib plus fulvestrant with or without palbociclib demonstrated improved efficacy versus fulvestrant alone in adult patients with HR-positive, HER2-negative PIK3CA wild-type metastatic breast cancer.
The Program in Progress will continue to be updated. View the current Program
